论文部分内容阅读
目的观察原发性肝癌组织中Ezrin蛋白表达的临床病理意义及其与患者预后相关性。方法回顾性分析68例肝癌患者的临床资料,用免疫组化法检测患者肝癌组织及远癌正常肝组织中Ezrin蛋白的表达情况。分析Ezrin蛋白在肝癌组织中的表达与临床病理学特征之间的关系及其与患者预后之间的相关性。结果 68例肝癌患者中肝癌组织和远癌正常肝组织Ezrin蛋白的表达阳性率分别为67.65%和16.18%,表达评分分别为(3.31±1.56),(0.56±1.21)分,肝癌组织中Ezrin蛋白阳性率及评分与正常肝组织相比,差异有统计学意义(P<0.05)。原发性肝癌转移患者癌组织中Ezrin阳性表达率为80.00%(32/40例),原发性肝癌未转移患者癌组织中Ezrin阳性表达率为50.00%(14/28例),Ezrin阳性表达与原发性肝癌转移相关(P<0.05);与患者年龄、性别、肿瘤分化程度及肿瘤大小等无明显相关性(P>0.05)。Ezrin蛋白阳性患者中位生存时间为31.10个月,阴性患者平均生存时间为36.10个月(P<0.05)。结论 Ezrin蛋白在人原发性肝癌中阳性表达率较高,且与患者预后不良有关。
Objective To observe the clinicopathological significance of Ezrin protein expression in primary hepatocellular carcinoma and its relationship with the prognosis of patients. Methods The clinical data of 68 patients with liver cancer were retrospectively analyzed. The expression of Ezrin protein in liver cancer tissues and normal liver tissues of distant cancer patients was detected by immunohistochemistry. The relationship between the expression of Ezrin protein and clinicopathological features and the prognosis of HCC were analyzed. Results The positive rates of Ezrin protein expression in 68 HCC patients and 67 HCC patients with distant cancer were 67.65% and 16.18%, respectively (3.31 ± 1.56 and 0.56 ± 1.21), respectively. The positive rates of Ezrin protein The positive rate and score compared with normal liver tissue, the difference was statistically significant (P <0.05). The Ezrin positive rate was 80.00% (32/40 cases) in the primary liver cancer metastasis and 50.00% (14/28 cases) in the non-metastatic primary liver cancer. The positive expression of Ezrin (P <0.05). There was no significant correlation with age, sex, tumor differentiation and tumor size (P> 0.05). The median survival time was 31.10 months in Ezrin positive patients and 36.10 months in negative patients (P <0.05). Conclusion The positive rate of Ezrin protein in human primary hepatocellular carcinoma is high, which is related to the poor prognosis of patients.